|
GB201609742D0
|
|
Improvements relating to antibodies
|
|
GB201520499D0
|
|
Compounds
|
|
GB201520500D0
|
|
Compounds
|
|
GB201519549D0
|
|
Compounds
|
|
GB201419722D0
|
|
Compounds
|
|
GB201219478D0
|
|
Stabilised silicate compositions and their uses
|
|
GB201209096D0
|
|
Compounds
|
|
GB201104669D0
|
|
Compound
|
|
GB201008134D0
|
|
Compounds
|
|
CN102428084A
|
|
Compounds
|
|
EP2231704A2
|
|
Hepatitis c virus antibodies
|
|
GB0717683D0
|
|
Compositions and methods
|
|
GB0623892D0
|
|
Assay
|
|
GB0611444D0
|
|
Rnase H2 complex and genes therefor
|
|
GB0501202D0
|
|
Targets for therapy
|
|
GB0403476D0
|
|
Muscarinic agents
|
|
GB0322194D0
|
|
Compounds and their medical uses
|
|
GB0322195D0
|
|
Compounds and their medical uses
|
|
GB0303623D0
|
|
Muscarinic agents
|
|
GB0221954D0
|
|
Compounds and their medical uses
|
